Short term treatment with Escheria coli recombinant human granulocyte- macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease

M. Aglietta, F. Montemurro, F. Fagioli, C. Volta, B. Botto, M. Cantonetti, V. Racanelli, L. Teofili, R. Ferrara, S. Amadori, G. L. Castoldi, F. Dammacco, A. Levis

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Granulocyte-macrophage-colony stimulating factor (GM-CSF) administration stimulates the proliferation of hemopoietic progenitors. Shortly (48-96 hours) after its discontinuation, feedback phenomena occur and the progenitor proliferation rate drops below baseline levels. As the quiescence of hyperplastic bone marrow suggests that hemopoietic cells may be refractory to the toxic effects of cytostatic drugs, the decision was made to test the hypothesis that GM-CSF given before chemotherapy may be myeloprotective. METHODS. Fifty-six patients with newly diagnosed Stage II-IV Hodgkin disease, ages 18-77 years, were randomized to receive GM-CSF (5 μg/kg subcutaneously) or placebo from Day 7 to Day 4 before each chemotherapy administration (6 cycles of a hybrid of mechlorethamine, vincristine, procarbazine, and prednisone with doxorubicin, bleomycin, vinblastine, and dacarbazine). The treatment was considered a success if the delivery rate of chemotherapy was >90% after 3 cycles and >80% after 6 cycles. RESULTS. Thirty patients received GM-CSF and 26 placebo. The dose intensity (85.2% vs. 79.6%) and the overall success in terms of delivery rate (56.7% vs. 50%) were higher in the GM-CSF group, although these differences were not statistically significant. The neutrophil nadirs were higher in the GM-CSF group during the first three cycles and subsequently similar in both groups. CONCLUSIONS. No significant differences in terms of myelotoxicity or drug delivery were observed between the two treatment arms. Although the myeloprotective effect of the prechemotherapy administration of GM-CSF seems to be minimal, the data indicate a safe timing between GM-CSF discontinuation and further chemotherapy. Because cumulative myelotoxicity has been observed with other growth factors, given in the interval between the chemotherapy cycles, this may be relevant to the planning of rapid cycling.

Original languageEnglish
Pages (from-to)454-460
Number of pages7
JournalCancer
Volume88
Issue number2
DOIs
Publication statusPublished - Jan 15 2000

Keywords

  • Granulocyte- macrophage-colony stimulating factor
  • Hodgkin disease
  • Hybrid mechlorethamine
  • Myeloprotection
  • Vincristine, procarbazine, and prednisone, doxorubicin, bleomycin, vinblastine, and dacarbazine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Short term treatment with Escheria coli recombinant human granulocyte- macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease'. Together they form a unique fingerprint.

  • Cite this

    Aglietta, M., Montemurro, F., Fagioli, F., Volta, C., Botto, B., Cantonetti, M., Racanelli, V., Teofili, L., Ferrara, R., Amadori, S., Castoldi, G. L., Dammacco, F., & Levis, A. (2000). Short term treatment with Escheria coli recombinant human granulocyte- macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease. Cancer, 88(2), 454-460. https://doi.org/10.1002/(SICI)1097-0142(20000115)88:2<454::AID-CNCR28>3.0.CO;2-Q